{"id":900280,"date":"2025-10-27T06:15:34","date_gmt":"2025-10-27T10:15:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/"},"modified":"2025-10-27T06:15:34","modified_gmt":"2025-10-27T10:15:34","slug":"theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/","title":{"rendered":"Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p id=\"temp_ReleaseStart\">\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">DUBLIN<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 27, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on <span class=\"xn-chron\">Monday, November 10, 2025<\/span>. An accompanying conference call and simultaneous webcast will be hosted at <span class=\"xn-chron\">5:00 pm EST<\/span> (<span class=\"xn-chron\">2:00 pm PST<\/span> \/ <span class=\"xn-chron\">10:00 pm GMT<\/span>) that day.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.jpg\" title=\"Theravance Biopharma Logo (PRNewsfoto\/Theravance Biopharma, Inc.)\" alt=\"Theravance Biopharma Logo (PRNewsfoto\/Theravance Biopharma, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p class=\"prntaj\">\n        <b>Conference Call Information<\/b>\n      <\/p>\n<p class=\"prntaj\">To participate in the live call by telephone, please pre-register <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4541550-1&amp;h=3347032149&amp;u=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBId7f34fea811649b9a3a47e3ba29d2d2a&amp;a=here\" target=\"_blank\" rel=\"nofollow\">here<\/a>. Those interested in the live audio webcast of the conference call may access it by\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4541550-1&amp;h=2504006091&amp;u=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2Frqsptkbx&amp;a=clicking+here\" target=\"_blank\" rel=\"nofollow\">clicking here<\/a> or visiting the <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4541550-1&amp;h=1596218951&amp;u=https%3A%2F%2Finvestor.theravance.com%2Fevents-and-presentations&amp;a=Events+and+Presentation\" target=\"_blank\" rel=\"nofollow\">Events and Presentation<\/a> page under the Investors Section on <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4541550-1&amp;h=547360270&amp;u=http%3A%2F%2Fwww.theravance.com%2F&amp;a=Theravance+Biopharma%27s+website\" target=\"_blank\" rel=\"nofollow\">Theravance Biopharma&#8217;s website<\/a>.<\/p>\n<p class=\"prntaj\">A replay of the webcast will be available on Theravance Biopharma&#8217;s website for 30 days through <span class=\"xn-chron\">December 10, 2025<\/span>.<\/p>\n<p class=\"prntaj\">\n        <b>About Theravance Biopharma <\/b>\n      <\/p>\n<p class=\"prntaj\">Theravance Biopharma, Inc.&#8217;s focus is to deliver <i>Medicines that Make a Difference<\/i><sup>\u00ae<\/sup> in people&#8217;s lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI<sup>\u00ae<\/sup> (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating\/driving shareholder value.<\/p>\n<p class=\"prntaj\">For more information, please visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4541550-1&amp;h=234650679&amp;u=https%3A%2F%2Fwww.theravance.com%2F&amp;a=www.theravance.com\" target=\"_blank\" rel=\"nofollow\">www.theravance.com<\/a>.<\/p>\n<p class=\"prntaj\">THERAVANCE BIOPHARMA<sup>\u00ae<\/sup>, THERAVANCE<sup>\u00ae<\/sup> and the Cross\/Star logo are registered trademarks of the\u00a0Theravance Biopharma\u00a0group of companies (in the\u00a0U.S.\u00a0and certain other countries).<\/p>\n<p class=\"prntaj\">YUPELRI<sup>\u00ae<\/sup>\u202fis a registered trademark of\u202fViatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.<\/p>\n<p class=\"prntaj\">Contact:<br \/><a href=\"mailto:investor.relations@theravance.com\" target=\"_blank\" rel=\"nofollow\">investor.relations@theravance.com<\/a><br \/>650-808-4045<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=SF07076&amp;sd=2025-10-27\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025-302594981.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025-302594981.html<\/a><\/p>\n<p>SOURCE  Theravance Biopharma, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=SF07076&amp;Transmission_Id=202510270600PR_NEWS_USPR_____SF07076&amp;DateId=20251027\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire DUBLIN , Oct. 27, 2025 \/PRNewswire\/ &#8212;\u00a0Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST \/ 10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in the live audio webcast of the conference call may access it by\u00a0clicking here or visiting the Events and Presentation page under the Investors Section on Theravance Biopharma&#8217;s website. A replay of the webcast will be available on Theravance Biopharma&#8217;s website for 30 days through December 10, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-900280","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire DUBLIN , Oct. 27, 2025 \/PRNewswire\/ &#8212;\u00a0Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST \/ 10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in the live audio webcast of the conference call may access it by\u00a0clicking here or visiting the Events and Presentation page under the Investors Section on Theravance Biopharma&#8217;s website. A replay of the webcast will be available on Theravance Biopharma&#8217;s website for 30 days through December 10, &hellip; Continue reading &quot;Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-27T10:15:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025\",\"datePublished\":\"2025-10-27T10:15:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\\\/\"},\"wordCount\":319,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/557290\\\/Theravance_Biopharma_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\\\/\",\"name\":\"Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/557290\\\/Theravance_Biopharma_Logo.jpg\",\"datePublished\":\"2025-10-27T10:15:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/557290\\\/Theravance_Biopharma_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/557290\\\/Theravance_Biopharma_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/","og_locale":"en_US","og_type":"article","og_title":"Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 - Market Newsdesk","og_description":"PR Newswire DUBLIN , Oct. 27, 2025 \/PRNewswire\/ &#8212;\u00a0Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2025 financial results and provide a business update after market close on Monday, November 10, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST \/ 10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in the live audio webcast of the conference call may access it by\u00a0clicking here or visiting the Events and Presentation page under the Investors Section on Theravance Biopharma&#8217;s website. A replay of the webcast will be available on Theravance Biopharma&#8217;s website for 30 days through December 10, &hellip; Continue reading \"Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-27T10:15:34+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025","datePublished":"2025-10-27T10:15:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/"},"wordCount":319,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/","name":"Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.jpg","datePublished":"2025-10-27T10:15:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/557290\/Theravance_Biopharma_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/theravance-biopharma-to-report-third-quarter-2025-financial-results-on-november-10-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=900280"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/900280\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=900280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=900280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=900280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}